Lose-weight effect on high fat diet-induced obese mice of analogues of rimonabant ZH-101-S
WANG Jin1, ZHOU Bing-jie1, GEN Ji1, FENG Jian-ke2, FAN Ru-lin2, GUO Wen-jie1, GAO Jing1
(1. School of Pharmacy,Jiangsu University, Zhenjiang Jiangsu 212013; 2. Zhenjiang Tianjian New and Specialty Drug Research and Development Limited Company, Zhenjiang Jiangsu 212013, China)
Abstract:[Abstract]Objective: To investigate the mechanism of analogues of rimonabant ZH-101-S loseweight effect on highfat dietinduced obese mice. Methods: Male ICR mice were fed with high fat diet to build the obese mice model and the mice were divided into control group,obese model group,rimonabant group(30 mg/kg)and ZH-101-S group(15 mg/kg, 30 mg/kg).All drug were administered by intragastric administration per day for 18 days. Body weight and the content/morphology of genital peripheral adipose tissue and morphology of liver were detected, the content of total cholesterol,triacylglycerol,high density lipoprotein cholesterol(HDL-C), glucose, low density lipoprotein cholesterol(LDLC), glutamicoxalacetic transaminase(AST), glutamic-pyruvic transaminase(ALT) and lactic dehydrogenase(LDH) in serum were also estimated. Results: After treated with ZH101-S for 18 days, the bodyweight of mice and the content of genital peripheral adipose tissue were significantly reduced, compared with model group. ZH101-S could decrease the level of triacylglycerol,total cholesterol,LDL-C, LDH in serum and elevate the level of HDLC. Finally, ZH101S protected high fat food induced hepatic injury proved by AST and ALT decrease and improvement of liver morphology. Conclusion: ZH101S could reduce the bodyweight, improve plasma lipid profile and hepatic injury of highfat dietinduced obese mice.
收稿日期: 2015-11-03
基金资助:
镇江市新兴产业科技专项基金资助项目(CY2011026)
通讯作者:
高静(通讯作者),教授,博士生导师,E-mail:jinggao@ujs.edu.cn
作者简介: 王瑾(1990—),女,硕士研究生;
引用本文:
王瑾1, 周炳杰1, 耿骥1, 冯建科2, 范儒霖2, 郭文洁1, 高静1. 利莫那班衍生物对高脂肥胖模型小鼠的减肥作用[J]. 江苏大学学报:医学版, 2016, 26(02): 119-123.
WANG Jin1, ZHOU Bing-jie1, GEN Ji1, FENG Jian-ke2, FAN Ru-lin2, GUO Wen-jie1, GAO Jing1. Lose-weight effect on high fat diet-induced obese mice of analogues of rimonabant ZH-101-S. Journal of Jiangsu University(Medicine Edition), 2016, 26(02): 119-123.
\[1\]Matias I, Petrosino S, Racioppi A, et al. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: effect of high fat diets\[J\]. Mol Cell Endocrinol, 2008, 286(1/2 Suppl 1): S66-S78.\[2\]Adan RA. Mechanisms underlying current and future antiobesity drugs\[J\]. Trends Neurosci, 2013, 36(2): 133-140.\[3\]Filippatos TD, Derdemezis CS, Gazi IF, et al. Orlistatassociated adverse effects and drug interactions\[J\]. Drug Saf, 2008, 31(1): 53-65.\[4\]George M, Rajaram M, Shanmugam E. New and emerging drug molecules against obesity\[J\]. J Cardiovasc Pharmacol Ther, 2014, 19(1): 65-76.\[5\]Thomas BF, Francisco ME, Seltzman HH, et al. Synthesis of longchain amide analogs of the cannabinoid CB1 receptor antagonist N(piperidinyl)5(4chlorophenyl)1(2,4dichlorophenyl)4methyl1Hpyrazole3carboxamide(SR141716) with unique binding selectivities and pharmacological activities\[J\]. Bioorg Med Chem, 2005, 13(18): 5463-5474.\[6\]Leite CE, Mocelin CA, Petersen GO, et al. Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity\[J\]. Pharmacol Rep, 2009, 61(2): 217-224.\[7\]GaryBobo M, Elachouri G, Gallas JF, et al. Rimonabant reduces obesityassociated hepatic steatosis and features of metabolic syndrome in obese Zucker fa/fa rats\[J\]. Hepatology, 2007, 46(1): 122-129.\[8\]Van Gaal LF,Rissanen AM,Scheen AJ, et al. Effects of the cannabinoid1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients:1year experience from the RIOEurope Study\[J\]. Lancet, 2005, 365(9468): 1389-1397.\[9\]Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia \[J\]. N Engl J Med, 2005, 353(20): 2121-2134.\[10\]Jones D. End of the line for cannabinoid receptor 1 as an antiobesity target \[J\]. Nat Rev Drug Discov, 2008, 7(12): 961-962.\[11\]Takano A, Gulyas B, Varnas K, et al. Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study\[J\]. Synapse, 2014, 6(83): 89-97.\[12\]Starowiicz KM, Cristino L, Matias I, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a highfat diet\[J\]. Obesity, 2008, 16(3): 553-565.\[13\]Staehr P, HotherNielsen O, BeckNielsen H, et al. The role of the liver in type 2 diabetes\[J\]. Rev Endocr Metab Disord, 2004, 5(2): 105-110.\[14\]杨海冬, 高静, 李静, 等. 利莫那班改构物对高脂饮食诱导肥胖小鼠的减肥效应及机制\[J\]. 江苏大学学报: 医学版, 2012, 22(3): 231-235.